Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study

    January 2025 in “ Journal of Dermatological Treatment ”
    Carlo Alberto Vignoli, Luigi Gargiulo, Luciano Ibba, Anna Balato, Mauro Barbareschi, Stefania Barruscotti, Giulia Bazzacco, Francesco Bellinato, Vittoria Giulia Bianchi, Valeria Boccaletti, Raffaele D. Caposiena Caro, Silvia Mariel Ferrucci, Alessandro Fraghì, Elisabetta Fulgione, Giuseppe Gallo, Paolo Gisondi, Isotta Giunipero di Corteranzo, Piergiorgio Malagoli, Angelo Valerio Marzano, Santo Raffaele Mercuri, Diego Orsini, Pietro Quaglino, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
    TLDR Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
    This study assessed the effectiveness and safety of baricitinib, a JAK 1/2 inhibitor, for treating severe alopecia areata over 52 weeks in a real-world setting with 96 adult patients across 11 Italian Dermatology Units. The results indicated that 61.5% of patients achieved significant hair regrowth with a SALT score of ≤20. Additionally, 67.6% and 69.7% of patients showed substantial improvement in eyebrow and eyelash hair loss, respectively. While no severe adverse events were reported, 50% of patients experienced mild to moderate adverse events, such as weight gain. The study supports baricitinib as an effective and safe treatment for severe alopecia areata, aligning with previous clinical trials.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results